This study was designed to investigate the effect of laparoscopic gastrectomy on adjuvant chemotherapy in patients with gastric cancer.
Introduction
According to the recommendations of relevant clinical guidelines, if the pathological stage of the tumor is Ib with lymph node metastasis, or the stage is II or higher, adjuvant chemotherapy should be used in patients with R0 resection after undergoing surgery for gastric cancer. [1] [2] [3] [4] Studies have shown that early and full-dose adjuvant chemotherapy can improve the long-term survival of patients. [5] [6] [7] Since open gastrectomy (OG) for gastric cancer is highly invasive and patients recover slowly postoperatively, it often leads to delayed chemotherapy and an inadequate dosage. [8] Compared with open surgery, laparoscopic gastrectomy (LG) has many advantages, including less intraoperative blood loss, reduced postoperative pain, less postoperative release of inflammatory factors, and rapid recovery, and the long-term outcome is similar to that of open surgery. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] It has been reported that LG can improve the compliance with adjuvant chemotherapy in patients with colon cancer. [23] However, to the best of knowledge, no study has evaluated the effect of LG on adjuvant chemotherapy in patients with gastric cancer. Therefore, the study herein aims to examine the effect of LG on the compliance of adjuvant chemotherapy in patients with gastric cancer.
Patients and methods
This study complied with the ethical principles of the Declaration of Helsinki. This retrospective research study was approved by the ethics committee of our institution. The requirement for informed consent from all patients was waived because of the retrospective nature of this study.
From January 2008 to January 2015, 562 patients with gastric cancer received radical gastrectomy at our hospital. Of these, 269 patients received LG and 293 received OG. The indications for LG include clinical stage T1-3N0M0 and patients who receive no neoadjuvant therapy. However, medical insurance in China does not cover the costs of various surgical instruments used in LG, and LG is not listed in the treatment guidelines for gastric cancer. Therefore, if the patient's clinical stage is T1-3N0-1M0, the surgeon presents the available treatment regimens (laparoscopic or open gastrectomy) and then allows the patient to choose the surgical approach.
In this study, inclusion criteria were as follows: patients who met the aforementioned surgical indications, patients with R0 resection determined by a postoperative pathological examination, and patients who received at least 1 cycle of adjuvant chemotherapy after radical gastrectomy. Exclusion criteria were as follows: patients with incomplete clinical data and patients who underwent intraoperative removal of other organs. Two hundred six patients met the inclusion and exclusion criteria. Of these, 114 patients received LG and were included in the LG group, and 92 patients received OG and were included in the OG group. Staging of gastric carcinoma was based on the seventh edition of the TNM classification of gastric carcinoma, as proposed by the Union for International Cancer Control and American Joint Committee on Cancer. For patients operated on before 2010, staging was recalculated to match the seventh TNM classification. Specific surgical details have been previously described in the literature. [24] We reviewed postoperative mortality, defined as death within 30 days after the operation, and postoperative morbidity, defined as complications occurring within 30 postoperative days. Morbidity was graded according to the Clavien-Dindo classification. Major complications were defined as grades 3, 4, and 5, and minor complications were classified as grades 1 and 2. [25] Indications for adjuvant chemotherapy are tumors with a pathological stage Ib and lymph node metastasis or stage II and higher, and patients without contraindications to chemotherapy. The specific chemotherapy regimens were determined by medical oncologists. The chemotherapy regimens administered to patients were as follows: intravenous 5-fluorouracil combined with intravenous cisplatin, oral fluoropyrimidine and S-1, and oral S-1 and intravenous cisplatin. [26] The maximum number of cycles of chemotherapy was 6. The medical oncologists determined whether to delay chemotherapy or reduce the dosage of chemotherapy according to patients' symptoms, signs, and auxiliary examination results.
Patients were followed up with once every 3 months for the first 3 years postoperatively, once every 6 months for the fourth and fifth years, and subsequently, once every year. Follow-up examinations included brain, chest, and abdominal computed tomography examinations. If tumor recurrence was suggested based on the symptoms, timely hospital visits were provided. The last follow-up visit was in January 2016. Disease recurrence was defined as locoregional or distant metastasis confirmed by a radiology or pathology examination when appropriate. [27] Overall survival (OS) was assessed from the date of surgery until the last follow-up visit or death due to any cause. Diseasefree survival (DFS) was calculated from the date of surgery until the date of cancer recurrence or death due to any cause. SPSS software 13.0 for Windows (SPSS Inc, Chicago, IL) was used to perform the statistical analysis. Variables following a normal distribution are presented as a mean and standard deviation, and they were analyzed using the Student t test. Variables following a non-normal distribution are expressed as a median and range, and they were compared using the Wilcoxon test. Differences in the semiquantitative results were analyzed using the Mann-Whitney U test. Differences in the qualitative results were analyzed using the x 2 test or Fisher exact test, as appropriate. Survival rates were analyzed using the Kaplan-Meier method, and differences between the 2 groups were analyzed using the log-rank test. Univariate analyses were performed to identify prognostic variables related to OS. Univariate variables with P < .05 were selected for inclusion in the multivariate Cox proportional hazard regression model. Adjusted hazard ratios with corresponding 95% confidence intervals were calculated. P < .05 was considered statistically significant.
Results
As shown in Fig. 1 , the proportion of patients undergoing LG among the total number of patients each year was gradually increasing.
Patients in the 2 groups showed no significant difference in age, sex, the Eastern Cooperative Oncology Group performance status (PS) score, medical comorbidities, and pathological stage ( Table 1) . Advantages of LG included less intraoperative blood loss (P = .019), fewer postoperative complications (P = .027), few major complications (P = .033), and a shorter hospital stay (P = .031) ( Table 2 ). There were no significant differences in the Figure 1 . Proportion of patients undergoing LG among the total number of patients each year. LG = laparoscopic gastrectomy.
Table 1
Comparison of baseline characteristics between the 2 groups.
LG (n = 157) OG (n = 129) P value Table 2 Comparison of postoperative data between the 2 groups.
LG (n = 157) OG (n = 129) P value LG = laparoscopic gastrectomy, OG = open gastrectomy.
Bao (Table 3) . Compared with patients in the OG group, patients in the LG group had better compliance with adjuvant chemotherapy; specifically, patients received more cycles of adjuvant chemotherapy (P = .044), more patients received a full dose of onschedule adjuvant chemotherapy (delayed chemotherapy doses and reduced chemotherapy doses: P = .027 and.014, respectively), and more patients completed ≥75% of the planned dose (P = .000) ( Table 4 ). No significant difference in the time of the first adjuvant chemotherapy and the incidence of grade 3 or 4 chemotherapy toxicity was found between the 2 groups. The pathological TNM staging had no effect on compliance with adjuvant chemotherapy (Table 5 ).
The median follow-up duration was 30 months. The 5-year OS rates of patients in the LG group and OG group were 56% and 42%, respectively, and the difference was statistically significant (Fig. 2, P = .030) . The 5-year DFS rates in the LG and OG groups were 42% and 18%, respectively, and the difference was statistically significant (Fig. 3, P = .005) . Results of multivariate analysis showed that a higher T stage, higher N stage, less than 75% of total planned regimen without delay or dose reduction, reduced chemotherapy doses, and OG were independent predictors of a poor prognosis (Tables 6 and 7 ).
Discussion
Adjuvant chemotherapy plays an important role in the treatment of gastric cancer because of its effect on improving prognosis. [1] [2] [3] [4] Good compliance can enhance the efficacy of adjuvant Table 3 Comparison of pathological results between the 2 groups.
LG (n = 157) OG (n = 129) P value
Retrieved lymph nodes 18 (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) 20 (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) LG = laparoscopic gastrectomy, OG = open gastrectomy. Table 4 Comparison of chemotherapy compliance between the 2 groups.
LG (n = 157) OG (n = 129) P value chemotherapy and ultimately improve patients' long-term survival outcomes. [5] [6] [7] LG for gastric cancer has seen a rapid advancement in the past 10 years. [9] [10] [11] [12] [13] LG has the advantages of minimally invasive surgeries such as less blood loss, reduced postoperative pain, and a faster recovery. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] However, whether the advantages of the minimally invasive nature of LG can be translated into better compliance with adjuvant chemotherapy has not been reported. To our knowledge, the present study is the first report on compliance with adjuvant chemotherapy in patients with gastric cancer by LG, and we found that compliance can improve long-term survival outcomes.
The cycles of chemotherapy, dosage of chemotherapy, and presence of delayed chemotherapy are important indicators of compliance to chemotherapy. [28] The current study showed that compared with patients in the OG group, patients in the LG group were more compliant with chemotherapy. LG has many advantages in patients with gastric cancer such as less invasion and a rapid postoperative recovery. [29] [30] [31] In theory, patients in the LG group should start the first adjuvant chemotherapy earlier. However, in the present study, there was no significant difference in the start time of the first adjuvant chemotherapy between the 2 groups. The reason for this finding is that LG has been widely used in clinical practice for only more than 10 years, [5] [6] [7] [8] [9] [10] and the start time of adjuvant chemotherapy is still traditionally determined by the surgeons' experience during OG. The early initiation of adjuvant chemotherapy can improve patients' long-term survival; thus, the next step is to study whether adjuvant chemotherapy can be started earlier for patients undergoing LG.
Previous studies have shown that compliance with adjuvant chemotherapy is affected by many factors such as the type of resection, patients' age, PS score, and comorbidities. [32, 33] In the current study, the aforementioned factors in the 2 groups were not significantly different; therefore, the difference in compliance with adjuvant chemotherapy between the 2 groups can be attributed to the different surgical approaches.
The ultimate goal of adjuvant chemotherapy in patients with gastric cancer undergoing radical gastrectomy is to improve their long-term survival outcomes. In the present study, long-term OS and DFS rates were higher in the LG group than in the OG group. In addition, results of multivariate analysis indicated that the surgical approach is an independent predictor of prognosis. Therefore, the survival advantage for patients in the LG group can be attributed to the effect of LG on chemotherapy compliance.
There are certain differences in the therapeutic models for respectable gastric cancer between eastern and western countries. In eastern countries, surgical resection is performed first, followed by adjuvant therapy. [1] In western countries, patients with pathological stage ≥Ib receive neoadjuvant therapy first, followed by surgical resection; whereas patients with pathological stage ≥Ib who do not receive neoadjuvant therapy are given adjuvant therapy. [34] This study did not include patients who had undergone neoadjuvant therapy, as patients' treatment course for gastric cancer in this study followed the guidelines of eastern countries. Therefore, the conclusions reached in this study are only applicable to eastern countries, not to western countries.
The limitations of this study include its single-center, retrospective design, and other factors affecting patients' compliance with chemotherapy and prognosis that were not analyzed. Moreover, the median follow-up duration in this study was only 30 months, and the late recurrence of tumors and death of patients were not observed.
Conclusion
In summary, LG can improve the compliance of patients with gastric cancer with adjuvant chemotherapy, and this compliance can be translated into a survival advantage. We look forward to conducting prospective, multicenter, large-sample, randomized controlled trials to clarify this advantage as soon as possible. LG = laparoscopic gastrectomy, OG = open gastrectomy. Table 7 Multivariate Cox regression analyses of disease-free survival. 
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